Related Experiment Video
Updated: Feb 28, 2026
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
The Central Role of Endothelial Dysfunction in Cardiorenal Syndrome
Jun Zhang1, Teodoro Bottiglieri2, Peter A McCullough1,3,4,5
1Baylor Heart and Vascular Institute, TX, USA.
Insights
Endothelial dysfunction (ED) is a key factor in cardiorenal syndrome (CRS), progressing from reversible activation to irreversible cell death. Understanding this progression may improve treatments for CRS patients.
Area of Science:
- Cardiovascular Research
- Nephrology
- Endothelial Biology
Background:
- Endothelial dysfunction (ED) is a critical process in cardiorenal syndrome (CRS).
- ED is closely linked with cardiac and renal dysfunction, making it a key research and clinical target for CRS.
- The relationship between ED and CRS is a significant area of study.
Purpose of the Study:
- To elucidate the sequential cellular events in endothelial dysfunction.
- To differentiate between reversible and irreversible stages of ED.
- To explore the clinical implications of ED in cardiorenal syndrome.
Main Methods:
- Review of existing literature on endothelial activation, apoptosis, and necrosis.
- Analysis of the etiological factors contributing to ED.
- Examination of the role of ED in different types of CRS.
Main Results:
- ED progresses through distinct phases: type I and type II endothelial activation, followed by apoptosis and necrosis.
- ED can be categorized as reversible (activation) or irreversible (apoptosis, necrosis).
- Irreversible ED may explain the ineffectiveness of certain antihypertensive drugs in some CRS patients.
Conclusions:
- The progression of ED from reversible to irreversible states has potential clinical implications for CRS management.
- Factors like asymmetric dimethylarginine, nitric oxide, oxidative stress, and anti-endothelial cell antibodies contribute to ED.
- Further research is needed to confirm ED as a viable pharmacological target in CRS.
Background:
Endothelial dysfunction (ED) has emerged as a critical process in cardiorenal syndrome (CRS). The concept that ED is closely linked with cardiac and renal dysfunction has become an important target for CRS-related research and clinical practice.
Summary:
The sequence of events leading to ED is initiated by type I endothelial activation (almost immediately) and type II endothelial activation (over hours, days, and even months), followed by endothelial apoptosis and endothelial necrosis. The fact that ED is a continual cellular event divides this process into reversible ED (endothelial activation) and irreversible ED (endothelial apoptosis and necrosis). This basic research-defined concept may have clinical implications. Although most antihypertensive drugs (ACE inhibitors, statins, etc.) are effective in patients with hypertension and diabetes, some of them have proved to be ineffective, which may partly be attributed to irreversible ED. Even though the etiology of ED consists mainly of asymmetric dimethylarginine, nitric oxide, oxidative stress, and anti-endothelial cell antibodies, many other inducers of ED have been identified. In addition, a distinct role of ED has been reported for each type of CRS in humans.
Key Messages:
Further study is warranted to prove whether ED holds promise as a pharmacological target in CRS patients.
Related Concept Videos
01:29Hypertension II: Pathophysiology
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:29Heart Failure II: Pathophysiology
01:22Heart Failure Drugs: Diuretics
01:17Pathophysiology of Heart Failure
01:25Antihypertensive Drugs: Direct Renin Inhibitors